UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference

Clinical epigenetics, 2023-03, Vol.15 (1), p.36-36, Article 36

2023

Volltextzugriff (PDF)

Ambient fine particulate matter inhibits 15-lipoxygenases to promote lung carcinogenesis

Journal of experimental & clinical cancer research, 2019-08, Vol.38 (1), p.359-359, Article 359

2019

Volltextzugriff (PDF)

A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma

Investigational new drugs, 2021-10, Vol.39 (5), p.1375-1382

2021

Volltextzugriff (PDF)

Estrogen receptor alpha promotes smoking-carcinogen-induced lung carcinogenesis via cytochrome P450 1B1

Journal of molecular medicine (Berlin, Germany), 2015-11, Vol.93 (11), p.1221-1233

2015

Volltextzugriff (PDF)

An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma

Investigational new drugs, 2012-02, Vol.30 (1), p.387-394

2012

Volltextzugriff (PDF)

Anticancer efficacy of 5F in NNK-induced lung cancer development of A/J mice and human lung cancer cells

Journal of molecular medicine (Berlin, Germany), 2010-12, Vol.88 (12), p.1265-1276

2010

Volltextzugriff (PDF)

Clinicopathologic and Molecular Features of Epidermal Growth Factor Receptor T790M Mutation and c-MET Amplification in Tyrosine Kinase Inhibitor-resistant Chinese Non-small Cell Lung Cancer

Pathology oncology research, 2009-12, Vol.15 (4), p.651-658

2009

Volltextzugriff (PDF)

Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types

Journal for immunotherapy of cancer, 2024-02, Vol.12 (2), p.e008339

2024

Volltextzugriff (PDF)

Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

Drugs (New York, N.Y.), 2021-02, Vol.81 (2), p.257-266

2021

Volltextzugriff (PDF)

Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network

Supportive care in cancer, 2011-10, Vol.19 (10), p.1625-1635

2011

Volltextzugriff (PDF)

Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer

Drugs (New York, N.Y.), 2019-06, Vol.79 (8), p.823-831

2019

Volltextzugriff (PDF)

Clinical Outcomes with Erlotinib in Patients with Epidermal Growth Factor Receptor Mutation

Drugs (New York, N.Y.), 2012-01, Vol.72 (Suppl 1), p.3-10

2012

Volltextzugriff (PDF)

Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI

Clinical drug investigation, 2018-04, Vol.38 (4), p.319-331

2018

Volltextzugriff (PDF)

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

Journal for immunotherapy of cancer, 2022-02, Vol.10 (2), p.e003027

2022

Volltextzugriff (PDF)

KDR expression is associated with the stage and cigarette smoking of the patients with lung cancer

Journal of cancer research and clinical oncology, 2007-09, Vol.133 (9), p.635-642

2007

Volltextzugriff (PDF)

363 KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancer

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A390-A390

2021

Volltextzugriff (PDF)

364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A391-A391

2021

Volltextzugriff (PDF)

Clinical Outcomes with Erlotinib in Patients with Epidermal Growth Factor Receptor Mutation: Management of Non-Small Cell Lung Cancer: Focus on Erlotinib

Drugs (New York, N.Y.), 2012, Vol.72, p.3-10

2012

Volltextzugriff (PDF)

A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma

Cancer chemotherapy and pharmacology, 1999, Vol.44 (4), p.307-311

1999

Volltextzugriff (PDF)

The cost of palliative care for hepatocellular carcinoma in Hong Kong

PharmacoEconomics, 2001, Vol.19 (9), p.947-953

2001

Volltextzugriff (PDF)

Imatinib (STI-571) heals a gastrocutaneous fistula resulting from a malignant gastric stromal tumor

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2003-06, Vol.6 (2), p.122-126

2003

Volltextzugriff (PDF)

Phase II study of Temodal in the treatment of patients with advanced nasopharyngeal carcinoma

Cancer chemotherapy and pharmacology, 1998, Vol.42 (3), p.247-249

1998

Volltextzugriff (PDF)

FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer

Molecular cancer, 2017-07, Vol.16 (1), p.124-124, Article 124

2017

Volltextzugriff (PDF)

Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer

Current treatment options in oncology, 2018-11, Vol.19 (11), p.58-13, Article 58

2018

Volltextzugriff (PDF)

APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy

Hepatology international, 2021-10, Vol.15 (5), p.1031-1048

2021

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLink

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(44)

Sprache

Englisch
(44)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(34)
Science & Technology
(34)
Humans
(30)
Oncology
(22)
Medicine
(19)
Medicine & Public Health
(19)
Lung Cancer
(18)
Middle Aged
(16)
Chemotherapy
(15)
Female
(15)
Male
(14)
Patients
(13)
Aged
(12)
Mutation
(12)
Pharmacology & Pharmacy
(12)
Adult
(11)
Antineoplastic Agents - Therapeutic Use
(10)
Tumors
(10)
Cancer Therapies
(9)
Lung Neoplasms - Drug Therapy
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference

Ambient fine particulate matter inhibits 15-lipoxygenases to promote lung carcinogenesis

A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma

Estrogen receptor alpha promotes smoking-carcinogen-induced lung carcinogenesis via cytochrome P450 1B1

An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma

Anticancer efficacy of 5F in NNK-induced lung cancer development of A/J mice and human lung cancer cells

Clinicopathologic and Molecular Features of Epidermal Growth Factor Receptor T790M Mutation and c-MET Amplification in Tyrosine Kinase Inhibitor-resistant Chinese Non-small Cell Lung Cancer

Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types

Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network

Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer

Clinical Outcomes with Erlotinib in Patients with Epidermal Growth Factor Receptor Mutation

Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

KDR expression is associated with the stage and cigarette smoking of the patients with lung cancer

363 KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancer

364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status

Clinical Outcomes with Erlotinib in Patients with Epidermal Growth Factor Receptor Mutation: Management of Non-Small Cell Lung Cancer: Focus on Erlotinib

A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma

The cost of palliative care for hepatocellular carcinoma in Hong Kong

Imatinib (STI-571) heals a gastrocutaneous fistula resulting from a malignant gastric stromal tumor

Phase II study of Temodal in the treatment of patients with advanced nasopharyngeal carcinoma

FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer

Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer

APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy

Aktive Filter

Suchergebnisse filtern